CDH6 and ovarian cancer: AGS-16M8F study closed without reaching the maximal tolerated dose.109 AGS-16C3F entered the phase 2 study in pretreated RCC, but did not meet the primary PFS endpoint.110 Another potential target may be cadherin 6 (CDH6), a cell-adhesion molecule involved in epithelial-mesenchymal transition, given its high expression in RCC.111,112 DS-6000a, an antibody-drug conjugate composed of an anti-CDH6 monoclonal antibody attached to a deruxtecan payload, is under investigation in a phase I study of pretreated ovarian cancer and advanced RCC (NCT04707248).113